[AMENDMENT AGREEMENT TO NON-QUALIFIED STOCK OPTION AGREEMENTS OF CHINA PHARMA HOLDINGS, INC WHEREAS, the Employment Agreement by and between the Company and the Optionee will cease its effect as of April 28, 2012; WHEREAS, the Nominating and Compensation Committee believes it is for the best interest of the Company to terminate the Subject Options on April 28, 2012 and the]
[U.S.GAAP International Financial Reporting Standards issued STYLE="font-family:Times New Roman" SIZE="2">by the International Accounting Standards Board Other Page INTRODUCTION 1 PARTI 3 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT ANDVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THEMPANY] [LIST OF SUBSIDIARIES STYLE="font-family:Times New Roman" SIZE="2"> Mindray (UK) Limited,orporated in the United Kingdom Mindray Research and Development Limited,orporated in the British Virgin Islands Mindray Global Limited,orporated in the British Virgin Islands Shenzhen Mindray Bio-Medical Electronicsorporated in the Peoples Republic of China Beijing Shen Mindray Medical Electronics Technology Research Instituteorporated in the Peoples Republic of] [CERTIFICATION STYLE="font-family:Times New Roman" SIZE="2">I, Xu Hang, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION STYLE="font-family:Times New Roman" SIZE="2">I, Li Xiting, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION STYLE="font-family:Times New Roman" SIZE="2">I,ex Lung, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION Xu Hang Chairman and-Chief Executive Officer Li Xiting Director,PresidentandCo-ChiefExecutiveOfficerex Lung Chief Financial Officer d293110dex131.htm 6 EX-13.1] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM STYLE="font-family:Times New Roman" SIZE="2"> We herebynsent to theorporation by reference in the Registration Statement on FormS-8 (No. 333-178896) of Mindray Medical International Limited of our reportted April30, 2012 relating to the financial statements and the effectiveness of internalntrol over financial reporting, which appears in this Form 20-F. Wesonsent]
[U.S.GAAP International Financial Reporting Standards issued STYLE="font-family:Times New Roman" SIZE="2">by the International Accounting Standards Board Other Page INTRODUCTION 1 PARTI 3 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT ANDVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THEMPANY] [LIST OF SUBSIDIARIES STYLE="font-family:Times New Roman" SIZE="2"> Mindray (UK) Limited,orporated in the United Kingdom Mindray Research and Development Limited,orporated in the British Virgin Islands Mindray Global Limited,orporated in the British Virgin Islands Shenzhen Mindray Bio-Medical Electronicsorporated in the Peoples Republic of China Beijing Shen Mindray Medical Electronics Technology Research Instituteorporated in the Peoples Republic of] [CERTIFICATION STYLE="font-family:Times New Roman" SIZE="2">I, Xu Hang, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION STYLE="font-family:Times New Roman" SIZE="2">I, Li Xiting, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION STYLE="font-family:Times New Roman" SIZE="2">I,ex Lung, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION Xu Hang Chairman and-Chief Executive Officer Li Xiting Director,PresidentandCo-ChiefExecutiveOfficerex Lung Chief Financial Officer d293110dex131.htm 6 EX-13.1] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM STYLE="font-family:Times New Roman" SIZE="2"> We herebynsent to theorporation by reference in the Registration Statement on FormS-8 (No. 333-178896) of Mindray Medical International Limited of our reportted April30, 2012 relating to the financial statements and the effectiveness of internalntrol over financial reporting, which appears in this Form 20-F. Wesonsent]
[SCHEDULE 14A INFORMATION x o Check the appropriate box: x Preliminary Proxy Statement o o Definitive Proxy Statement o Definitiveditional Materials o Cleantech Solutions International, Payment of Filing Fee (Check the appropriate box): x No fee required. o Feemputed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.]
[Execution Version CONVERTIBLE NOTE PURCHASE among CHINA CORD BLOOD CORPORATION and KKR CHINA HEALTHCARE INVESTMENT LIMITED Dated April 12, 2012 Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OF CONTENTS Page Section 1 2 Section 2 9 Section 3 9 Section 4 14 Section 5] [SENIOR CONVERTIBLE NOTE SECURITIES ACT CHINA CORD BLOOD CORPORATION 7% SENIOR CONVERTIBLE NOTE Original Principal Amount: US$65,000,000 Holder Principal and Issuance Date and Note Notes Other Notes Registration Rights Agreement FOR VALUE RECEIVED, China Cord Blood Corporation, an exempted company with limited liability incorporated in the Cayman Islands (the “Company”), hereby promises to pay to the order of KKR China] [EXECUTION COPY REGISTRATION RIGHTS AGREEMENT between CHINA CORD BLOOD CORPORATION and KKR CHINA HEALTHCARE INVESTMENT LIMITED April 27 Dated Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OF CONTENTS Page Section 1 DEFINITIONS 1 Section 2 GENERAL; SECURITIES SUBJECT TO THIS AGREEMENT 5 Section 3] [DIRECTOR INDEMNIFICATION AGREEMENT between CHINA CORD BLOOD CORPORATION and JULIAN J. WOLHARDT Dated April 27, 2012 Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OF CONTENTS Contents Page 1. Interpretation 1 2. Indemnity 3 3. Limitations on indemnity 3 4. Company’s liability 4 5. 4] [Execution Copy INDEMNIFICATION PRIORITY AND INFORMATION SHARING AGREEMENT Agreement KKR CHINA HEALTHCARE INVESTMENT LIMITED Investor KKR Company This INDEMNIFICATION PRIORITY AND INFORMATION SHARING AGREEMENT, dated as of April 27, 2012 (this “ Company Indemnification Agreement KKR Indemnified Parties WHEREAS, the Company has entered into a Convertible Note Purchase Agreement dated as of April 12, 2012 (the “ KKR Director WHEREAS,] [China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR HONG KONG, China, April 27, 2012 China Cord Blood Corporation (NYSE: CO) (“CCBC” or “the Company”), the first and largest cord blood banking operator in China, today announced that it has successfully closed a US$65 million convertible debt financing with funds affiliated with KKR China Growth]
[Execution Version CONVERTIBLE NOTE PURCHASE among CHINA CORD BLOOD CORPORATION and KKR CHINA HEALTHCARE INVESTMENT LIMITED Dated April 12, 2012 Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OF CONTENTS Page Section 1 2 Section 2 9 Section 3 9 Section 4 14 Section 5] [SENIOR CONVERTIBLE NOTE SECURITIES ACT CHINA CORD BLOOD CORPORATION 7% SENIOR CONVERTIBLE NOTE Original Principal Amount: US$65,000,000 Holder Principal and Issuance Date and Note Notes Other Notes Registration Rights Agreement FOR VALUE RECEIVED, China Cord Blood Corporation, an exempted company with limited liability incorporated in the Cayman Islands (the “Company”), hereby promises to pay to the order of KKR China] [EXECUTION COPY REGISTRATION RIGHTS AGREEMENT between CHINA CORD BLOOD CORPORATION and KKR CHINA HEALTHCARE INVESTMENT LIMITED April 27 Dated Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OF CONTENTS Page Section 1 DEFINITIONS 1 Section 2 GENERAL; SECURITIES SUBJECT TO THIS AGREEMENT 5 Section 3] [DIRECTOR INDEMNIFICATION AGREEMENT between CHINA CORD BLOOD CORPORATION and JULIAN J. WOLHARDT Dated April 27, 2012 Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OF CONTENTS Contents Page 1. Interpretation 1 2. Indemnity 3 3. Limitations on indemnity 3 4. Company’s liability 4 5. 4] [Execution Copy INDEMNIFICATION PRIORITY AND INFORMATION SHARING AGREEMENT Agreement KKR CHINA HEALTHCARE INVESTMENT LIMITED Investor KKR Company This INDEMNIFICATION PRIORITY AND INFORMATION SHARING AGREEMENT, dated as of April 27, 2012 (this “ Company Indemnification Agreement KKR Indemnified Parties WHEREAS, the Company has entered into a Convertible Note Purchase Agreement dated as of April 12, 2012 (the “ KKR Director WHEREAS,] [China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR HONG KONG, China, April 27, 2012 China Cord Blood Corporation (NYSE: CO) (“CCBC” or “the Company”), the first and largest cord blood banking operator in China, today announced that it has successfully closed a US$65 million convertible debt financing with funds affiliated with KKR China Growth]
[Press Releases Safe Harbor Statement 99.1 Press release regarding financial results for the first quarter ended March 31, 2012. CHANGYOU.COM LIMITED Alex Ho, Chief Financial Officer]
[Press Releases Safe Harbor Statement 99.1 Press release regarding financial results for the first quarter ended March 31, 2012. CHANGYOU.COM LIMITED Alex Ho, Chief Financial Officer]
[Press Releasesfe Harbor Statement 99.1 Press release regarding financial results for the first quarter ended March31, 2012. CHANGYOU.COM LIMITEDex Ho, Chief Financial Officer Description 99.1 Press Release regarding financial results for the first quarter ended March 31, 2012. Changyou Reports First Quarter 2012 Unaudited Financial Results Total Revenues and Non-GAAP Netome for the First Quarter]
[ITEM 1 IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISORS 1 ITEM 2 OFFER STATISTICS AND EXPECTED TIMETABLE 1 ITEM 3 KEY INFORMATION 1 ITEM 4 INFORMATION ON THE COMPANY 29 ITEM 4A UNRESOLVED STAFF COMMENTS 45 ITEM 5 OPERATING AND FINANCIAL REVIEW AND PROSPECTS 45 ITEM 6 DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 71 ITEM 7 MAJOR SHAREHOLDERS AND RELATED PARTY] [1. Hanwha SolarOne U.S.A. Inc. (USA) 2. Hanwha SolarOne Investment Holding Ltd. (BVI) 3. Hanwha SolarOne Hong Kong Limited (Hong Kong) 4. Hanwha SolarOne (Nantong) Co., Ltd. (PRC) 5. Hanwha SolarOne (Qidong) Co., Ltd. (PRC) 6. Hanwha SolarOne Deutschland GmbH (Germany) 7. Hanwha SolarOne (Shanghai) Co., Ltd. (PRC) 8. Hanwha Solar Engineering Research and Development Center Co., Ltd. (PRC) 9.] [SARBANES-OXLEY ACT OF 2002 I, Ki-Joon Hong, certify that: 1. I have reviewed this annual report on Form 20-F of Hanwha SolarOne Co., Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER SARBANES-OXLEY ACT OF 2002 I, Jung Pyo Seo, certify that: 1. I have reviewed this annual report on Form 20-F of Hanwha SolarOne Co., Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [CERTIFICATION SARBANES-OXLEY ACT OF 2002 Ki-Joon Hong Chairman and Chief Executive Officer Jung Pyo Seo Chief Financial Officer] [Consent of Independent Registered Public Accounting Firm Shanghai, Peoples Republic of China April 30, 2012]
